Category

Archives

Others

Treatment of γ-Hydroxybutyric Acid (GHB) and γ-Butyrolactone (GBL) Overdose with Two Potent Monocarboxylate Transporter 1 (MCT1) Inhibitors, AZD3965 and AR-C155858

228 views | Apr 29 2019

Follman KE et al. indicated that inhibition of MCT1 is an effective treatment for GHB/GBL overdose. SIGNIFICANCE STATEMENT: This research demonstrates the efficacy of a potent MCT1 inhibitor, AZD2965, as a treatment for GHB overdose. AZD3965 was shown to reduce the brain exposure of GHB, and therefore reduce the toxic impact of GHB. This compound may have the potential to be developed to treat GHB overdose clinically. [Read the Full Post]

MicroRNA-24-1 suppresses mouse hepatoma cell invasion and metastasis via directly targeting O-GlcNAc transferase

252 views | Jan 14 2019

Liu Y et al. suggested that as a tumor suppressor, miR-24-1 may regulate mouse hepatocarcinoma cells migration and invasion, at least partially through targeting OGT, which could regulate the O-GlcNAcylation and the stability of this oncoprotein c-Myc. This may give insight into a novel mechanism and therapy of tumor lymphatic metastasis. [Read the Full Post]

MicroRNA-24-1 suppresses mouse hepatoma cell invasion and metastasis via directly targeting O-GlcNAc transferase

0 views | Jan 14 2019

Liu Y et al. suggested that as a tumor suppressor, miR-24-1 may regulate mouse hepatocarcinoma cells migration and invasion, at least partially through targeting OGT, which could regulate the O-GlcNAcylation and the stability of this oncoprotein c-Myc. This may give insight into a novel mechanism and therapy of tumor lymphatic metastasis. [Read the Full Post]

SIRT1 prevents hyperuricemia via the PGC-1α/PPARγ-ABCG2 pathway

437 views | Dec 17 2018

Wang J et al. demonstrated that SIRT1 and its activator, RSV, have clear anti-hyperuricemia functions in this mouse model. One possible mechanism is the activation of ABCG2 in the ileum through the PGC-1α/PPARγ pathway. [Read the Full Post]

MicroRNA-24-1 suppresses mouse hepatoma cell invasion and metastasis via directly targeting O-GlcNAc transferase

153 views | Dec 17 2018

Liu Y et al. suggested that as a tumor suppressor, miR-24-1 may regulate mouse hepatocarcinoma cells migration and invasion, at least partially through targeting OGT, which could regulate the O-GlcNAcylation and the stability of this oncoprotein c-Myc. This may give insight into a novel mechanism and therapy of tumor lymphatic metastasis. [Read the Full Post]

Cytokine correlation analysis based on drug perturbation

0 views | Dec 09 2018

Wallner FK et al. showed that cytokines are highly co-regulated, which provide valuable information for how a therapeutic drug might affect clusters of cytokines. In addition, a cytokine that is used as a therapeutic biomarker could be combined with its related cytokines into a biomarker panel to improve diagnostic accuracy. [Read the Full Post]

Cell-based assay system for high-throughput screening of anti-photo-aging agents in fibroblast transfectants

0 views | Dec 07 2018

Lee S et al. revealed that CCN1-GFs treated with sclareol showed decreased levels of UVB-induced CCN1 expression. Sclareol attenuated UVB-induced photo-aging by an increase in collagen synthesis and decrease in MMP-1 activity. [Read the Full Post]

Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer

199 views | Nov 05 2018

Zhang F et al. provided new insights into the therapeutic activity of Dihydroartemisinin as a treatment for gallbladder cancer metastasis. [Read the Full Post]

Dichloroacetate induces regulatory T-cell differentiation and suppresses Th17-cell differentiation by pyruvate dehydrogenase kinase-independent mechanism

333 views | Sep 12 2018

Makita N et al. indicated that Dichloroacetate possesses Treg induction and Th17 suppression, which is independent of PDHK and dependent on ROS production. [Read the Full Post]

Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells

356 views | Sep 07 2018

Gu HR et al. found that the combination of silibinin with either sorafenib or gefitinib could be a useful treatment approach for HCC in the future. [Read the Full Post]